Skip to content
Wenlo
Sign in
← Markets
Market open · Closes 4:00 PM ET

INSM Insmed Incorporated

NASDAQ
$112.58+$0.99 (+0.89%)

As of 3:59:00 PM ET · 2 days old

Loading chart…

Open
$113.60
Previous close
$111.59
Day range
111.97 – 116.37
52-week range
90.39 – 212.75
Volume
5.2M
Avg volume (3M)
2.9M
Market cap
$24.7B
P/E (TTM)
−17.54
EPS (TTM)
−$4.10
Beta
—
Dividend yield
0.00%
Next earnings
—
Ex-dividend
—
Sector
Healthcare

About Insmed Incorporated

Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions. The company’s pipeline emphasizes innovative approaches such as oral therapies and inhaled medicines designed to address difficult-to-treat respiratory disorders. Insmed also conducts research across multiple scientific platforms, including protein engineering and other advanced drug-development technologies. Headquartered in Bridgewater, New Jersey, Insmed serves patients and healthcare providers in the United States, Europe, Japan, and other international markets, positioning itself as a specialist in rare-disease and specialty respiratory treatment.

INSM news and filings

Loading filings…

Filings from SEC EDGAR.